Many historical drug failures can be attributed to problems in pharmacokinetics and bioavailability. It is possible to minimize the risk of such failures by using various in vitro assays that help at an early stage to identify molecules with better absorption, distribution, metabolism, excretion, and toxicity (ADMET) characteristics.
In order to support its medicinal chemistry programs, Evotec has developed a suite of in vitro assays that can be used to identify potential liabilities in early-stage compounds and to support the design of improved compounds during lead optimization. For selected clients, Evotec also provides ADMET services on a stand-alone basis.
In the case of certain in vitro assessments, such as protein binding for example, Evotec can offer a screening assay for earlier stage compounds and an in-depth assay for more advanced compounds. This facilitates assessment of more compounds at earlier stages of the project.
Beyond these in vitro assessments, Evotec ADMET scientists also use LC/MS/MS to perform bioanalysis and can generate and interpret typical parameters such as bioavailability, AUC, MRT, half-life, clearance and volume of distribution.